Pharmacosmos was established in 1965 by Henry Christensen MD, PhD, who was succeeded by his youngest son Lars Christensen, MD, as CEO in 1993. The company has since its establishment remained an independent family owned company.
The first 500 m2 manufacturing site - site Viby - was established in 1965 in a former dairy in a small village about 40 kilometres from the current site Holbaek. The original manufacturing site was expanded to approximately 1800 m2 in 1973.
Originally, the company was an API manufacturer of dextran powder of clinical grade, pharmacopoeial quality for production of infusion solutions and iron complexes. The API was and is still available in powder and/or bulk solutions for the manufacturing of veterinary iron dextran injection.
The company gained GMP approval from Danish Ministry of Health early-on, followed by a number of US FDA approvals after a 1983 US FDA inspection carried out by Mr Charles A. Wayne.
Investigator-lead landmark study in 1,137 patients with CHF and iron deficiency supported by the British Heart Foundation and Pharmacosmos, and published in the Lancet.
Pharmacosmos acquires all rights for AbFero’s SP-420 to advance iron chelation therapies
In 2020 Pharmacosmos etablished a subsidary in Beijing, China.
In 2020 Pharmacosmos etablished a subsidary in Beijing, China.
Monoferic was approved by FDA in January 2020 and launched in the US in October 2020.
In 2019 Pharmacosmos etablished a subsidary in New Jersey, US.
In 2019 Pharmacosmos etablished a subsidary in New Jersey, US.
In 2017 Pharmacosmos etablished a subsidary in Wiesbaden in Germany.
Head-to-Head study of risk of serious hypersensitivity with Monofer® versus iron sucrose in 3,000 patients with IDA
Head-to-Head study of risk of serious hypersensitivity with Monofer® versus iron sucrose in 3,000 patients with IDA
DEAE-Dextran is used for a number of applications hereunder as vaccine adjuvant, in gene therapy, and protein stabilization
In 2015 Pharmacosmos celebrated its 50 years anniversary
In 2015 Pharmacosmos celebrated its 50 years anniversary
500 m2 Expansion of site Holbaek - synthesis of derivatives (DEAE and others). Read more
In 2010 Pharmacosmos consolidated its sales activities in Denmark, Norway and Sweden
In 2010 Pharmacosmos consolidated its sales activities in Denmark, Norway and Sweden
In July 2010 Pharmacosmos UK Ltd, formerly Vitaline Pharmaceuticals Ltd, was established
Establishment of own Clinical Research and Medical Affairs departments
Launch of dextran in "small-pack" units with focus on broad dextran applications
Launch of dextran in "small-pack" units with focus on broad dextran applications
Take over of clinical grade dextran supply from Amersham Biosciences
Inauguration of new 13.000 m2 cGMP manufacturing facility in Holbaek, Denmark - initiates transformation from API manufacturer to development and marketing of pharmaceutical specialties
Supply agreement with Abbott and FDA approval for supply of API in the US
Supply agreement with Abbott and FDA approval for supply of API in the US
In 1989 Pharmacosmos established a subsidiary in New Jersey in the US to support the sales of its veterinary products.
FDA approval of 10% iron dextran bulk solution for veterinary use
FDA approval of 10% iron dextran bulk solution for veterinary use
The original manufacturing site was expanded to approximately 1800 m2 in 1973
The original manufacturing site was expanded to approximately 1800 m2 in 1973
The first 500 m2 manufacturing site was established in 1965 in a former dairy in a small village about 40 kilometres from the current site Holbaek
Pharmacosmos was established in 1965 by Henry Christensen MD, PhD, who was succeeded by his youngest son Lars Christensen, MD, as CEO in 1994. The company has since its establishment remained an independent family owned company
Pharmacosmos was established in 1965 by Henry Christensen MD, PhD, who was succeeded by his youngest son Lars Christensen, MD, as CEO in 1994. The company has since its establishment remained an independent family owned company
